| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 307 | 2024 | 20824 | 7.270 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 81 | 2023 | 948 | 7.110 |
Why?
|
| Breast | 80 | 2023 | 1970 | 5.870 |
Why?
|
| Carcinoma, Ductal, Breast | 61 | 2023 | 1100 | 5.110 |
Why?
|
| Carcinoma in Situ | 54 | 2023 | 806 | 4.270 |
Why?
|
| Mastectomy, Segmental | 44 | 2020 | 956 | 4.260 |
Why?
|
| Carcinoma, Lobular | 26 | 2022 | 484 | 3.380 |
Why?
|
| Carcinoma | 23 | 2023 | 2375 | 2.900 |
Why?
|
| Breast Diseases | 32 | 2021 | 443 | 2.740 |
Why?
|
| Phyllodes Tumor | 4 | 2021 | 53 | 1.890 |
Why?
|
| Neoplasm Recurrence, Local | 78 | 2023 | 9240 | 1.770 |
Why?
|
| Carcinoma, Papillary | 7 | 2021 | 783 | 1.680 |
Why?
|
| Receptors, Estrogen | 40 | 2024 | 2190 | 1.420 |
Why?
|
| Fibrocystic Breast Disease | 12 | 2017 | 102 | 1.390 |
Why?
|
| Frozen Sections | 4 | 2013 | 155 | 1.310 |
Why?
|
| Cadherins | 9 | 2022 | 907 | 1.290 |
Why?
|
| Immunohistochemistry | 46 | 2022 | 11366 | 1.260 |
Why?
|
| Receptor, erbB-2 | 28 | 2023 | 2417 | 1.170 |
Why?
|
| Radiation Oncology | 7 | 2016 | 555 | 1.070 |
Why?
|
| Carcinoma, Acinar Cell | 2 | 2023 | 61 | 1.000 |
Why?
|
| Precancerous Conditions | 15 | 2016 | 975 | 0.990 |
Why?
|
| Neoadjuvant Therapy | 7 | 2022 | 2727 | 0.970 |
Why?
|
| Hyperplasia | 30 | 2023 | 1185 | 0.930 |
Why?
|
| Neoplasm, Residual | 8 | 2022 | 973 | 0.920 |
Why?
|
| Neoplasm Invasiveness | 35 | 2023 | 3616 | 0.890 |
Why?
|
| Biopsy, Needle | 12 | 2008 | 1641 | 0.890 |
Why?
|
| Pathology, Clinical | 8 | 2019 | 368 | 0.890 |
Why?
|
| Female | 318 | 2024 | 380193 | 0.860 |
Why?
|
| Receptors, Steroid | 1 | 2023 | 155 | 0.840 |
Why?
|
| Mucocele | 1 | 2022 | 49 | 0.830 |
Why?
|
| Epithelial Cells | 16 | 2014 | 3690 | 0.790 |
Why?
|
| Adenocarcinoma, Mucinous | 6 | 2022 | 507 | 0.720 |
Why?
|
| Fibroma | 1 | 2021 | 212 | 0.700 |
Why?
|
| Biopsy | 42 | 2020 | 6755 | 0.690 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2023 | 298 | 0.680 |
Why?
|
| Humans | 358 | 2024 | 744366 | 0.660 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 2019 | 200 | 0.650 |
Why?
|
| Breast Neoplasms, Male | 1 | 2019 | 210 | 0.620 |
Why?
|
| In Situ Hybridization, Fluorescence | 8 | 2023 | 2649 | 0.600 |
Why?
|
| Sex Reassignment Surgery | 2 | 2020 | 130 | 0.580 |
Why?
|
| Gene Fusion | 1 | 2019 | 371 | 0.570 |
Why?
|
| Mammary Glands, Human | 6 | 2021 | 199 | 0.560 |
Why?
|
| Receptors, Progesterone | 24 | 2018 | 1098 | 0.560 |
Why?
|
| Lymph Nodes | 11 | 2021 | 3476 | 0.540 |
Why?
|
| Genes, BRCA1 | 6 | 2014 | 781 | 0.520 |
Why?
|
| Isocitrate Dehydrogenase | 2 | 2020 | 871 | 0.510 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2019 | 1018 | 0.500 |
Why?
|
| Hemangiosarcoma | 1 | 2017 | 239 | 0.500 |
Why?
|
| Mammography | 24 | 2012 | 2475 | 0.460 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 4 | 2020 | 1038 | 0.420 |
Why?
|
| Prognosis | 58 | 2022 | 29060 | 0.410 |
Why?
|
| Mastectomy | 21 | 2019 | 1793 | 0.410 |
Why?
|
| Pathology | 3 | 2022 | 272 | 0.410 |
Why?
|
| Radiography, Interventional | 2 | 2019 | 1095 | 0.400 |
Why?
|
| Lymphatic Metastasis | 23 | 2019 | 2924 | 0.400 |
Why?
|
| Middle Aged | 144 | 2023 | 213390 | 0.390 |
Why?
|
| Practice Guidelines as Topic | 4 | 2017 | 7282 | 0.390 |
Why?
|
| Neoplasm Staging | 36 | 2021 | 11031 | 0.370 |
Why?
|
| Neoplasms, Multiple Primary | 7 | 2015 | 604 | 0.370 |
Why?
|
| Diagnosis, Differential | 20 | 2021 | 12961 | 0.370 |
Why?
|
| Gene Expression Profiling | 13 | 2020 | 9445 | 0.350 |
Why?
|
| Fibroadenoma | 2 | 2016 | 43 | 0.350 |
Why?
|
| Adult | 132 | 2022 | 214052 | 0.350 |
Why?
|
| Genetic Association Studies | 2 | 2020 | 2703 | 0.340 |
Why?
|
| Stromal Cells | 9 | 2021 | 1355 | 0.330 |
Why?
|
| Combined Modality Therapy | 38 | 2019 | 8642 | 0.330 |
Why?
|
| Radiotherapy, Adjuvant | 12 | 2017 | 1771 | 0.330 |
Why?
|
| Genes, erbB-2 | 6 | 2007 | 162 | 0.330 |
Why?
|
| Axilla | 12 | 2019 | 597 | 0.330 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2011 | 390 | 0.320 |
Why?
|
| Risk Factors | 53 | 2021 | 72296 | 0.310 |
Why?
|
| Pathology, Surgical | 2 | 2014 | 155 | 0.310 |
Why?
|
| Reference Standards | 2 | 2021 | 1025 | 0.300 |
Why?
|
| Nipples | 3 | 2023 | 219 | 0.300 |
Why?
|
| Tumor Suppressor Protein p53 | 8 | 2016 | 2949 | 0.300 |
Why?
|
| Patient Selection | 2 | 2019 | 4216 | 0.300 |
Why?
|
| Breast Cyst | 1 | 2006 | 8 | 0.290 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 2938 | 0.290 |
Why?
|
| Observer Variation | 9 | 2015 | 2593 | 0.270 |
Why?
|
| Immunoenzyme Techniques | 12 | 2013 | 1799 | 0.270 |
Why?
|
| Neovascularization, Pathologic | 7 | 2022 | 2638 | 0.270 |
Why?
|
| Medical Oncology | 6 | 2023 | 2267 | 0.270 |
Why?
|
| Epithelium | 7 | 2017 | 1679 | 0.260 |
Why?
|
| Aged | 87 | 2022 | 163288 | 0.260 |
Why?
|
| Chemotherapy, Adjuvant | 15 | 2022 | 3480 | 0.260 |
Why?
|
| Consensus | 6 | 2023 | 2960 | 0.250 |
Why?
|
| Heterozygote | 3 | 2012 | 2804 | 0.250 |
Why?
|
| Immunophenotyping | 6 | 2023 | 1880 | 0.250 |
Why?
|
| Aged, 80 and over | 41 | 2022 | 57776 | 0.250 |
Why?
|
| Receptors, Androgen | 4 | 2019 | 1058 | 0.250 |
Why?
|
| Ki-67 Antigen | 4 | 2023 | 644 | 0.250 |
Why?
|
| Tissue Array Analysis | 9 | 2012 | 553 | 0.250 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2019 | 710 | 0.250 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2017 | 17446 | 0.240 |
Why?
|
| Catenins | 2 | 2021 | 41 | 0.230 |
Why?
|
| Cell Nucleus | 8 | 2011 | 2969 | 0.230 |
Why?
|
| Biological Products | 2 | 2022 | 860 | 0.220 |
Why?
|
| Papilloma, Intraductal | 2 | 2020 | 22 | 0.220 |
Why?
|
| Keratins | 7 | 2011 | 515 | 0.220 |
Why?
|
| Antineoplastic Agents, Hormonal | 6 | 2019 | 1524 | 0.220 |
Why?
|
| Case-Control Studies | 22 | 2021 | 21748 | 0.210 |
Why?
|
| Receptors, Thyroid Hormone | 1 | 2023 | 202 | 0.210 |
Why?
|
| Specimen Handling | 4 | 2018 | 694 | 0.210 |
Why?
|
| Salivary Glands | 1 | 2023 | 229 | 0.210 |
Why?
|
| Mucins | 2 | 2022 | 564 | 0.210 |
Why?
|
| Parity | 4 | 2021 | 929 | 0.210 |
Why?
|
| Gene Expression | 6 | 2017 | 7798 | 0.200 |
Why?
|
| Societies, Medical | 6 | 2016 | 3743 | 0.200 |
Why?
|
| Cohort Studies | 25 | 2022 | 40559 | 0.200 |
Why?
|
| Calcinosis | 7 | 2014 | 1499 | 0.190 |
Why?
|
| Mutation | 12 | 2020 | 29786 | 0.190 |
Why?
|
| Predictive Value of Tests | 14 | 2021 | 15078 | 0.190 |
Why?
|
| Microscopy | 2 | 2017 | 902 | 0.190 |
Why?
|
| Tamoxifen | 5 | 2019 | 981 | 0.190 |
Why?
|
| Neoplasm Proteins | 8 | 2007 | 3707 | 0.180 |
Why?
|
| Paris | 1 | 2019 | 42 | 0.180 |
Why?
|
| Odds Ratio | 12 | 2017 | 9849 | 0.180 |
Why?
|
| Follow-Up Studies | 37 | 2020 | 39052 | 0.180 |
Why?
|
| Diagnostic Errors | 3 | 2017 | 1257 | 0.180 |
Why?
|
| BRCA1 Protein | 5 | 2016 | 1149 | 0.180 |
Why?
|
| Drug Therapy | 1 | 2003 | 497 | 0.170 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2014 | 415 | 0.170 |
Why?
|
| United States | 26 | 2020 | 69872 | 0.170 |
Why?
|
| Estrogen Replacement Therapy | 3 | 2013 | 1203 | 0.170 |
Why?
|
| Microtomy | 2 | 1997 | 47 | 0.170 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2022 | 890 | 0.170 |
Why?
|
| Urothelium | 1 | 2021 | 277 | 0.170 |
Why?
|
| Carcinoma, Ductal | 2 | 2010 | 101 | 0.170 |
Why?
|
| Receptor, erbB-3 | 1 | 2020 | 142 | 0.170 |
Why?
|
| Alcohol Drinking | 5 | 2013 | 3966 | 0.170 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2017 | 3326 | 0.170 |
Why?
|
| Image Processing, Computer-Assisted | 6 | 2020 | 8949 | 0.160 |
Why?
|
| Risk | 16 | 2021 | 9688 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2019 | 318 | 0.160 |
Why?
|
| Disease Progression | 14 | 2016 | 13286 | 0.160 |
Why?
|
| Physician-Patient Relations | 1 | 2012 | 3229 | 0.160 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1999 | 224 | 0.160 |
Why?
|
| Endothelial Growth Factors | 4 | 2002 | 694 | 0.160 |
Why?
|
| Decision Making | 1 | 2012 | 3888 | 0.160 |
Why?
|
| Prospective Studies | 35 | 2020 | 53290 | 0.160 |
Why?
|
| Communication | 1 | 2012 | 3750 | 0.160 |
Why?
|
| Plasma Cells | 1 | 2021 | 591 | 0.150 |
Why?
|
| Necrosis | 4 | 2019 | 1643 | 0.150 |
Why?
|
| Cyclooxygenase 2 | 2 | 2011 | 612 | 0.150 |
Why?
|
| Gene Rearrangement | 1 | 2023 | 1179 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2022 | 11525 | 0.150 |
Why?
|
| Lymphokines | 4 | 2002 | 949 | 0.150 |
Why?
|
| Postmenopause | 6 | 2019 | 2460 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2016 | 8432 | 0.150 |
Why?
|
| Expert Testimony | 1 | 2020 | 356 | 0.150 |
Why?
|
| Sarcoma | 2 | 2021 | 1897 | 0.150 |
Why?
|
| Cyclophosphamide | 4 | 2020 | 2242 | 0.150 |
Why?
|
| Cicatrix | 2 | 2002 | 764 | 0.140 |
Why?
|
| Muscle Cells | 2 | 2009 | 197 | 0.140 |
Why?
|
| Reproducibility of Results | 9 | 2020 | 19905 | 0.140 |
Why?
|
| Patient Care Management | 1 | 2020 | 306 | 0.140 |
Why?
|
| Risk Assessment | 12 | 2021 | 23336 | 0.140 |
Why?
|
| Receptors, Growth Factor | 3 | 2002 | 334 | 0.140 |
Why?
|
| Doxorubicin | 3 | 2020 | 2234 | 0.140 |
Why?
|
| Urogenital Neoplasms | 1 | 2017 | 137 | 0.140 |
Why?
|
| Retrospective Studies | 32 | 2022 | 77460 | 0.130 |
Why?
|
| Sensitivity and Specificity | 14 | 2006 | 14723 | 0.130 |
Why?
|
| Nuclear Proteins | 1 | 2010 | 5856 | 0.130 |
Why?
|
| Menarche | 2 | 2021 | 516 | 0.130 |
Why?
|
| Antigens, CD | 4 | 2021 | 4026 | 0.130 |
Why?
|
| Germ-Line Mutation | 2 | 2017 | 1788 | 0.130 |
Why?
|
| Nurses | 8 | 2017 | 2462 | 0.130 |
Why?
|
| Coloring Agents | 2 | 1997 | 566 | 0.130 |
Why?
|
| Stereotaxic Techniques | 3 | 2014 | 536 | 0.130 |
Why?
|
| Young Adult | 10 | 2022 | 56429 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 4 | 2017 | 1062 | 0.120 |
Why?
|
| Watchful Waiting | 1 | 2019 | 492 | 0.120 |
Why?
|
| Consensus Development Conferences, NIH as Topic | 1 | 2014 | 28 | 0.120 |
Why?
|
| Prostate | 1 | 2003 | 1775 | 0.120 |
Why?
|
| Neoplasm Metastasis | 12 | 2014 | 4851 | 0.120 |
Why?
|
| Nanomedicine | 1 | 2017 | 304 | 0.120 |
Why?
|
| Incidence | 19 | 2020 | 20952 | 0.120 |
Why?
|
| Myocardium | 5 | 1993 | 4772 | 0.120 |
Why?
|
| Radiotherapy | 6 | 2014 | 1533 | 0.120 |
Why?
|
| Cisplatin | 1 | 2020 | 1662 | 0.120 |
Why?
|
| Testosterone | 2 | 2023 | 2419 | 0.110 |
Why?
|
| DNA Copy Number Variations | 2 | 2022 | 1941 | 0.110 |
Why?
|
| Treatment Outcome | 23 | 2014 | 63107 | 0.110 |
Why?
|
| Nomograms | 1 | 2015 | 228 | 0.110 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 1405 | 0.110 |
Why?
|
| Cytoplasm | 4 | 2011 | 1536 | 0.110 |
Why?
|
| Carbon | 1 | 1997 | 687 | 0.110 |
Why?
|
| Stem Cells | 3 | 2013 | 3567 | 0.110 |
Why?
|
| Estrogen Receptor alpha | 2 | 2014 | 577 | 0.110 |
Why?
|
| Molecular Biology | 2 | 2010 | 596 | 0.110 |
Why?
|
| Coxsackievirus Infections | 1 | 1993 | 44 | 0.110 |
Why?
|
| Androgens | 1 | 2020 | 1281 | 0.110 |
Why?
|
| Transcription Factors | 3 | 2011 | 12207 | 0.110 |
Why?
|
| Adolescent | 18 | 2019 | 85779 | 0.110 |
Why?
|
| Survival Analysis | 10 | 2014 | 10252 | 0.110 |
Why?
|
| Antineoplastic Protocols | 2 | 2002 | 50 | 0.110 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 4 | 2002 | 1660 | 0.110 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2021 | 3595 | 0.110 |
Why?
|
| American Cancer Society | 1 | 2012 | 61 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2013 | 323 | 0.110 |
Why?
|
| Blotting, Western | 3 | 2016 | 5181 | 0.110 |
Why?
|
| Oncogene Proteins, Viral | 1 | 1994 | 362 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor A | 6 | 2011 | 3511 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 5 | 1999 | 4554 | 0.100 |
Why?
|
| Mammaplasty | 2 | 2018 | 1204 | 0.100 |
Why?
|
| Genes, p53 | 4 | 2006 | 755 | 0.100 |
Why?
|
| Lymph Node Excision | 8 | 2019 | 1262 | 0.100 |
Why?
|
| Papilloma | 2 | 2008 | 148 | 0.100 |
Why?
|
| Mesothelioma | 1 | 2017 | 818 | 0.100 |
Why?
|
| Logistic Models | 8 | 2016 | 13409 | 0.100 |
Why?
|
| Mitosis | 2 | 2011 | 1208 | 0.100 |
Why?
|
| Molecular Typing | 1 | 2011 | 106 | 0.100 |
Why?
|
| Proportional Hazards Models | 12 | 2016 | 12356 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 3 | 2016 | 6171 | 0.100 |
Why?
|
| Technetium Tc 99m Sestamibi | 2 | 2002 | 177 | 0.100 |
Why?
|
| DNA Mutational Analysis | 2 | 2016 | 4185 | 0.100 |
Why?
|
| Neoplasms, Basal Cell | 1 | 2010 | 31 | 0.090 |
Why?
|
| Reproductive History | 3 | 2014 | 209 | 0.090 |
Why?
|
| Ovarian Neoplasms | 4 | 2017 | 4839 | 0.090 |
Why?
|
| Endocardium | 1 | 1992 | 263 | 0.090 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2015 | 332 | 0.090 |
Why?
|
| Time Factors | 19 | 2018 | 40075 | 0.090 |
Why?
|
| Fibrin | 1 | 1993 | 506 | 0.090 |
Why?
|
| Aneuploidy | 2 | 2011 | 530 | 0.090 |
Why?
|
| Molecular Imaging | 1 | 2017 | 828 | 0.090 |
Why?
|
| Survival Rate | 10 | 2019 | 12788 | 0.090 |
Why?
|
| Dietary Fiber | 3 | 2010 | 760 | 0.090 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 990 | 0.090 |
Why?
|
| Diet | 4 | 2014 | 7937 | 0.090 |
Why?
|
| Disease-Free Survival | 8 | 2021 | 6896 | 0.090 |
Why?
|
| Menopause | 5 | 2021 | 1626 | 0.090 |
Why?
|
| Chemokines, CXC | 2 | 2008 | 422 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2022 | 9955 | 0.080 |
Why?
|
| Staining and Labeling | 3 | 2005 | 1101 | 0.080 |
Why?
|
| Histological Techniques | 3 | 2017 | 198 | 0.080 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 1993 | 851 | 0.080 |
Why?
|
| Calcium-Binding Proteins | 2 | 2005 | 1081 | 0.080 |
Why?
|
| Registries | 3 | 2020 | 8091 | 0.080 |
Why?
|
| Cell Lineage | 3 | 2013 | 2504 | 0.080 |
Why?
|
| Atherectomy, Coronary | 3 | 1993 | 148 | 0.080 |
Why?
|
| Adenocarcinoma | 7 | 2004 | 6364 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2010 | 216 | 0.080 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2021 | 2249 | 0.080 |
Why?
|
| Apoptosis | 5 | 2010 | 9724 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2019 | 3024 | 0.080 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 2213 | 0.080 |
Why?
|
| Endometriosis | 1 | 2016 | 839 | 0.080 |
Why?
|
| Early Detection of Cancer | 2 | 2020 | 3086 | 0.080 |
Why?
|
| Terminology as Topic | 2 | 2013 | 1547 | 0.080 |
Why?
|
| Endometrial Neoplasms | 1 | 2017 | 1351 | 0.080 |
Why?
|
| DNA | 2 | 2022 | 7294 | 0.080 |
Why?
|
| Genes, Neoplasm | 1 | 2010 | 376 | 0.080 |
Why?
|
| Granuloma | 2 | 1987 | 319 | 0.080 |
Why?
|
| Nuts | 1 | 2010 | 257 | 0.080 |
Why?
|
| Myocarditis | 2 | 1993 | 771 | 0.080 |
Why?
|
| Sublingual Gland | 1 | 1987 | 10 | 0.080 |
Why?
|
| Cathepsins | 1 | 2008 | 241 | 0.080 |
Why?
|
| Heat-Shock Proteins | 1 | 2011 | 822 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2011 | 2943 | 0.080 |
Why?
|
| Salivary Gland Diseases | 1 | 1987 | 37 | 0.070 |
Why?
|
| Congresses as Topic | 1 | 2012 | 764 | 0.070 |
Why?
|
| Sialadenitis | 1 | 1987 | 43 | 0.070 |
Why?
|
| Age Factors | 14 | 2020 | 18373 | 0.070 |
Why?
|
| Secondary Prevention | 1 | 2013 | 1530 | 0.070 |
Why?
|
| Carcinoma, Large Cell | 1 | 2007 | 113 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 1998 | 1434 | 0.070 |
Why?
|
| Paraffin | 2 | 1996 | 35 | 0.070 |
Why?
|
| Phenotype | 9 | 2017 | 16367 | 0.070 |
Why?
|
| Skin Neoplasms | 4 | 2017 | 5692 | 0.070 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2012 | 1142 | 0.070 |
Why?
|
| Histocompatibility Antigens | 1 | 1987 | 471 | 0.070 |
Why?
|
| Codon, Nonsense | 1 | 2007 | 281 | 0.070 |
Why?
|
| Diagnosis-Related Groups | 1 | 1988 | 455 | 0.070 |
Why?
|
| Unnecessary Procedures | 1 | 2010 | 432 | 0.070 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2010 | 687 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2013 | 3921 | 0.070 |
Why?
|
| Intestine, Large | 1 | 2005 | 71 | 0.070 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 1987 | 129 | 0.070 |
Why?
|
| DNA, Neoplasm | 3 | 2013 | 1758 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2023 | 9647 | 0.070 |
Why?
|
| Folic Acid | 1 | 2012 | 1300 | 0.060 |
Why?
|
| Trigeminal Nerve | 1 | 1987 | 249 | 0.060 |
Why?
|
| Coronary Disease | 4 | 1993 | 6077 | 0.060 |
Why?
|
| Factor VIII | 2 | 1998 | 347 | 0.060 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2007 | 241 | 0.060 |
Why?
|
| Melanoma | 2 | 2017 | 5511 | 0.060 |
Why?
|
| Craniopharyngioma | 1 | 1987 | 281 | 0.060 |
Why?
|
| Ultrasonography, Mammary | 2 | 2004 | 250 | 0.060 |
Why?
|
| Managed Care Programs | 1 | 2010 | 950 | 0.060 |
Why?
|
| Multivariate Analysis | 8 | 2014 | 12244 | 0.060 |
Why?
|
| Microwaves | 3 | 1991 | 191 | 0.060 |
Why?
|
| Dietary Fats | 3 | 2014 | 2016 | 0.060 |
Why?
|
| Histones | 1 | 2014 | 2598 | 0.060 |
Why?
|
| Microcirculation | 3 | 2002 | 1287 | 0.060 |
Why?
|
| Cell Communication | 2 | 2009 | 1621 | 0.060 |
Why?
|
| Tissue Fixation | 2 | 2018 | 241 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2017 | 4034 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 2736 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factors | 4 | 2002 | 772 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2021 | 35425 | 0.060 |
Why?
|
| Keratin-7 | 1 | 2023 | 57 | 0.060 |
Why?
|
| Antibodies | 2 | 2008 | 2460 | 0.060 |
Why?
|
| Family Health | 2 | 2006 | 1281 | 0.050 |
Why?
|
| Cell Division | 7 | 2004 | 4569 | 0.050 |
Why?
|
| Male | 25 | 2022 | 350115 | 0.050 |
Why?
|
| Radiotherapy Dosage | 6 | 2004 | 2879 | 0.050 |
Why?
|
| S100 Proteins | 4 | 2005 | 259 | 0.050 |
Why?
|
| Computational Biology | 1 | 2014 | 3519 | 0.050 |
Why?
|
| Women's Health | 5 | 2004 | 2034 | 0.050 |
Why?
|
| World Health Organization | 2 | 2020 | 1318 | 0.050 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2001 | 61 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2006 | 624 | 0.050 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2010 | 2016 | 0.050 |
Why?
|
| Biology | 1 | 2024 | 295 | 0.050 |
Why?
|
| Antigens | 2 | 1987 | 1466 | 0.050 |
Why?
|
| Tumor Burden | 3 | 2013 | 1915 | 0.050 |
Why?
|
| Lymphatic Vessel Tumors | 1 | 2001 | 2 | 0.050 |
Why?
|
| Neoplasms | 4 | 2021 | 21696 | 0.050 |
Why?
|
| Colonic Diseases | 1 | 1983 | 202 | 0.050 |
Why?
|
| Keratin-5 | 2 | 2011 | 46 | 0.050 |
Why?
|
| DNA Repair | 1 | 2010 | 2046 | 0.050 |
Why?
|
| Radiopharmaceuticals | 2 | 2002 | 2645 | 0.050 |
Why?
|
| Cell Proliferation | 3 | 2014 | 10483 | 0.050 |
Why?
|
| Body Mass Index | 4 | 2021 | 12721 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 6 | 2007 | 6313 | 0.050 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 1983 | 264 | 0.050 |
Why?
|
| Membrane Proteins | 3 | 2007 | 7882 | 0.050 |
Why?
|
| Genes, erbB | 1 | 2000 | 5 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2011 | 3749 | 0.050 |
Why?
|
| In Situ Hybridization | 4 | 2002 | 1950 | 0.050 |
Why?
|
| Hematoxylin | 2 | 1993 | 64 | 0.050 |
Why?
|
| Eosine Yellowish-(YS) | 2 | 1993 | 72 | 0.050 |
Why?
|
| Cardiology | 1 | 1992 | 1668 | 0.050 |
Why?
|
| Skin | 2 | 1993 | 4372 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2010 | 15535 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2014 | 3841 | 0.050 |
Why?
|
| Meningeal Neoplasms | 2 | 1987 | 1241 | 0.050 |
Why?
|
| RNA, Messenger | 7 | 2013 | 13035 | 0.050 |
Why?
|
| Autoanalysis | 1 | 2000 | 72 | 0.050 |
Why?
|
| Lymphatic Irradiation | 1 | 2000 | 103 | 0.050 |
Why?
|
| Genetic Variation | 2 | 2020 | 6542 | 0.050 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2013 | 496 | 0.050 |
Why?
|
| Ploidies | 1 | 2000 | 281 | 0.040 |
Why?
|
| Esthetics | 3 | 1998 | 306 | 0.040 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2022 | 345 | 0.040 |
Why?
|
| Antineoplastic Agents | 5 | 2014 | 13693 | 0.040 |
Why?
|
| Cardiomyopathies | 1 | 1992 | 1912 | 0.040 |
Why?
|
| Autophagy | 1 | 2007 | 1297 | 0.040 |
Why?
|
| Regression Analysis | 7 | 2010 | 6459 | 0.040 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 3 | 2002 | 664 | 0.040 |
Why?
|
| Lymphocytes | 1 | 1987 | 2617 | 0.040 |
Why?
|
| Aspirin | 1 | 2011 | 3283 | 0.040 |
Why?
|
| Intestine, Small | 1 | 2005 | 1240 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2013 | 2505 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 5223 | 0.040 |
Why?
|
| Calcium | 1 | 2012 | 5755 | 0.040 |
Why?
|
| Hormone Replacement Therapy | 1 | 2004 | 745 | 0.040 |
Why?
|
| Elasticity | 1 | 2021 | 657 | 0.040 |
Why?
|
| Hepatocyte Growth Factor | 2 | 1997 | 270 | 0.040 |
Why?
|
| Edema | 1 | 1983 | 789 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2008 | 2887 | 0.040 |
Why?
|
| Saphenous Vein | 2 | 1992 | 532 | 0.040 |
Why?
|
| Pituitary Neoplasms | 1 | 1987 | 1345 | 0.040 |
Why?
|
| Estrogen Antagonists | 1 | 2019 | 152 | 0.040 |
Why?
|
| Graft Occlusion, Vascular | 2 | 1992 | 549 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2009 | 2684 | 0.040 |
Why?
|
| Research Design | 3 | 2011 | 5984 | 0.040 |
Why?
|
| Vitamin D | 1 | 2012 | 3224 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 539 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2006 | 1708 | 0.040 |
Why?
|
| Mass Screening | 2 | 2012 | 5253 | 0.040 |
Why?
|
| Health Care Costs | 2 | 2004 | 3208 | 0.040 |
Why?
|
| Hormones | 1 | 2022 | 889 | 0.040 |
Why?
|
| Cell Line, Tumor | 5 | 2014 | 16690 | 0.040 |
Why?
|
| Aminopyridines | 1 | 2021 | 542 | 0.040 |
Why?
|
| Age Distribution | 2 | 2014 | 2902 | 0.040 |
Why?
|
| Body Size | 1 | 2021 | 461 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2013 | 4751 | 0.040 |
Why?
|
| SEER Program | 2 | 2013 | 1507 | 0.040 |
Why?
|
| Recurrence | 8 | 2011 | 8340 | 0.040 |
Why?
|
| Meningioma | 1 | 1986 | 1209 | 0.040 |
Why?
|
| Mastectomy, Simple | 2 | 1993 | 24 | 0.040 |
Why?
|
| Nephrosis, Lipoid | 1 | 2017 | 51 | 0.040 |
Why?
|
| Quality Control | 1 | 2000 | 841 | 0.040 |
Why?
|
| Clinical Competence | 2 | 2014 | 4687 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 2018 | 299 | 0.040 |
Why?
|
| Analysis of Variance | 3 | 2021 | 6366 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2018 | 437 | 0.040 |
Why?
|
| Radiation Injuries | 1 | 1984 | 1180 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2001 | 1097 | 0.040 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2001 | 547 | 0.040 |
Why?
|
| Cell Differentiation | 4 | 2017 | 11486 | 0.040 |
Why?
|
| Benzimidazoles | 1 | 2021 | 850 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2003 | 2634 | 0.030 |
Why?
|
| Lactation | 1 | 1999 | 412 | 0.030 |
Why?
|
| Cell Polarity | 1 | 2020 | 645 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2018 | 353 | 0.030 |
Why?
|
| Risk Management | 1 | 2020 | 571 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 8861 | 0.030 |
Why?
|
| Mediator Complex | 1 | 2016 | 109 | 0.030 |
Why?
|
| beta Catenin | 1 | 2021 | 1059 | 0.030 |
Why?
|
| Laboratories | 1 | 2000 | 463 | 0.030 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2016 | 170 | 0.030 |
Why?
|
| Gene Library | 3 | 2004 | 1074 | 0.030 |
Why?
|
| Adiposity | 1 | 2005 | 1806 | 0.030 |
Why?
|
| Fibrosis | 2 | 2012 | 2029 | 0.030 |
Why?
|
| Coronary Vessels | 5 | 1993 | 3107 | 0.030 |
Why?
|
| Transforming Growth Factor alpha | 1 | 1996 | 135 | 0.030 |
Why?
|
| Vitamins | 1 | 2004 | 1623 | 0.030 |
Why?
|
| Receptors, Cell Surface | 2 | 2007 | 2865 | 0.030 |
Why?
|
| Mice, SCID | 2 | 2011 | 2716 | 0.030 |
Why?
|
| Pregnancy | 4 | 2013 | 29144 | 0.030 |
Why?
|
| Aromatase Inhibitors | 1 | 2019 | 490 | 0.030 |
Why?
|
| Adolescent Behavior | 1 | 2003 | 1151 | 0.030 |
Why?
|
| Vacuum | 1 | 2014 | 65 | 0.030 |
Why?
|
| Population Surveillance | 2 | 2017 | 2616 | 0.030 |
Why?
|
| Exercise | 1 | 2011 | 5615 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 2 | 2011 | 1602 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 6539 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2005 | 2921 | 0.030 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2016 | 431 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2007 | 5172 | 0.030 |
Why?
|
| Animals | 13 | 2017 | 168768 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 1995 | 588 | 0.030 |
Why?
|
| Crohn Disease | 1 | 1987 | 2304 | 0.030 |
Why?
|
| Tunica Intima | 2 | 1993 | 464 | 0.030 |
Why?
|
| Cytodiagnosis | 1 | 1998 | 435 | 0.030 |
Why?
|
| Hot Temperature | 1 | 2000 | 1356 | 0.030 |
Why?
|
| RNA, Neoplasm | 3 | 2002 | 769 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 1997 | 1263 | 0.030 |
Why?
|
| Mastectomy, Subcutaneous | 1 | 1993 | 46 | 0.030 |
Why?
|
| Growth Substances | 1 | 1996 | 784 | 0.030 |
Why?
|
| Intermediate Filaments | 1 | 2014 | 175 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 4 | 2007 | 9274 | 0.030 |
Why?
|
| DNA Methylation | 4 | 2010 | 4285 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2000 | 2453 | 0.030 |
Why?
|
| Microdissection | 1 | 2013 | 152 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 13104 | 0.030 |
Why?
|
| ROC Curve | 2 | 2014 | 3528 | 0.030 |
Why?
|
| Tomography, Optical Coherence | 1 | 2005 | 2657 | 0.030 |
Why?
|
| Antigens, Neoplasm | 2 | 2011 | 1988 | 0.030 |
Why?
|
| Epidermal Growth Factor | 1 | 1996 | 709 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 2001 | 1415 | 0.030 |
Why?
|
| Salvage Therapy | 2 | 2005 | 1275 | 0.030 |
Why?
|
| Quality of Life | 2 | 2012 | 12802 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 3 | 1989 | 1681 | 0.030 |
Why?
|
| Estrogens | 1 | 1999 | 1566 | 0.030 |
Why?
|
| Angioplasty, Balloon | 2 | 1987 | 653 | 0.030 |
Why?
|
| False Positive Reactions | 2 | 2005 | 980 | 0.030 |
Why?
|
| Keratin-6 | 1 | 2011 | 18 | 0.030 |
Why?
|
| Treatment Failure | 3 | 2006 | 2618 | 0.030 |
Why?
|
| Angioplasty, Laser | 1 | 1991 | 21 | 0.030 |
Why?
|
| Mice, Inbred C3H | 1 | 1993 | 964 | 0.030 |
Why?
|
| Micronutrients | 1 | 2014 | 375 | 0.030 |
Why?
|
| Entosis | 1 | 2011 | 6 | 0.030 |
Why?
|
| Methylation | 1 | 2014 | 1106 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2004 | 3296 | 0.020 |
Why?
|
| Receptors, Calcitriol | 1 | 2014 | 348 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2013 | 5974 | 0.020 |
Why?
|
| Biological Evolution | 1 | 2017 | 1077 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 1996 | 1677 | 0.020 |
Why?
|
| Integrin alpha6 | 1 | 2010 | 30 | 0.020 |
Why?
|
| Cell Adhesion | 2 | 2008 | 3144 | 0.020 |
Why?
|
| Epidemiologic Studies | 1 | 2014 | 676 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2001 | 2850 | 0.020 |
Why?
|
| Mice, Nude | 2 | 2009 | 3689 | 0.020 |
Why?
|
| Metaplasia | 1 | 2011 | 313 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2012 | 440 | 0.020 |
Why?
|
| Nutritional Requirements | 1 | 2012 | 286 | 0.020 |
Why?
|
| Molecular Sequence Data | 4 | 2011 | 18111 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2009 | 69 | 0.020 |
Why?
|
| Body Height | 1 | 2016 | 1578 | 0.020 |
Why?
|
| Temperature | 1 | 1996 | 2204 | 0.020 |
Why?
|
| Lysine | 1 | 2014 | 1007 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2002 | 3280 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 2 | 2008 | 2007 | 0.020 |
Why?
|
| Cytokinesis | 1 | 2011 | 177 | 0.020 |
Why?
|
| Thrombospondin 1 | 2 | 2002 | 250 | 0.020 |
Why?
|
| Endothelium, Vascular | 2 | 1999 | 4459 | 0.020 |
Why?
|
| Japan | 1 | 1993 | 1360 | 0.020 |
Why?
|
| Cathepsin K | 1 | 2008 | 68 | 0.020 |
Why?
|
| Neprilysin | 1 | 2011 | 439 | 0.020 |
Why?
|
| Medical Audit | 1 | 2010 | 467 | 0.020 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2013 | 602 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 1996 | 1677 | 0.020 |
Why?
|
| Paget Disease, Extramammary | 1 | 1988 | 45 | 0.020 |
Why?
|
| BRCA2 Protein | 1 | 2013 | 794 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2009 | 354 | 0.020 |
Why?
|
| Myosin Type II | 1 | 2007 | 68 | 0.020 |
Why?
|
| Cells, Cultured | 3 | 2013 | 19233 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2010 | 424 | 0.020 |
Why?
|
| Fluorouracil | 2 | 1989 | 1619 | 0.020 |
Why?
|
| Arteriosclerosis | 1 | 1992 | 1092 | 0.020 |
Why?
|
| Angioplasty, Balloon, Coronary | 2 | 1992 | 1873 | 0.020 |
Why?
|
| Glycoproteins | 1 | 1996 | 2266 | 0.020 |
Why?
|
| User-Computer Interface | 1 | 2014 | 1431 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2010 | 767 | 0.020 |
Why?
|
| Adherens Junctions | 1 | 2007 | 90 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2009 | 658 | 0.020 |
Why?
|
| Radionuclide Imaging | 2 | 2002 | 2031 | 0.020 |
Why?
|
| Down-Regulation | 2 | 2005 | 3001 | 0.020 |
Why?
|
| Mice | 6 | 2011 | 81201 | 0.020 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2009 | 320 | 0.020 |
Why?
|
| Fibronectins | 2 | 2002 | 726 | 0.020 |
Why?
|
| Reoperation | 2 | 2006 | 4201 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2013 | 1813 | 0.020 |
Why?
|
| Keratin-14 | 1 | 2006 | 57 | 0.020 |
Why?
|
| Cytokines | 1 | 2001 | 7323 | 0.020 |
Why?
|
| Immunochemistry | 1 | 1986 | 124 | 0.020 |
Why?
|
| Hematoporphyrins | 1 | 1985 | 23 | 0.020 |
Why?
|
| rho-Associated Kinases | 1 | 2007 | 279 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 10943 | 0.020 |
Why?
|
| California | 1 | 2010 | 1402 | 0.020 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2007 | 293 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2010 | 1879 | 0.020 |
Why?
|
| Primary Prevention | 1 | 2013 | 1167 | 0.020 |
Why?
|
| Esophagus | 1 | 1992 | 1019 | 0.020 |
Why?
|
| Methotrexate | 2 | 1989 | 1728 | 0.020 |
Why?
|
| Actuarial Analysis | 3 | 1994 | 378 | 0.020 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2005 | 103 | 0.020 |
Why?
|
| Vaginal Smears | 1 | 1988 | 511 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2012 | 2715 | 0.020 |
Why?
|
| Vinblastine | 1 | 2007 | 502 | 0.020 |
Why?
|
| Collagenases | 1 | 2005 | 228 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2011 | 2088 | 0.020 |
Why?
|
| Algorithms | 2 | 2021 | 13882 | 0.020 |
Why?
|
| Coronary Artery Bypass | 2 | 1992 | 2288 | 0.020 |
Why?
|
| Actins | 2 | 2007 | 2121 | 0.020 |
Why?
|
| Heart Valves | 1 | 1987 | 291 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2007 | 684 | 0.020 |
Why?
|
| Meninges | 1 | 1986 | 190 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2006 | 513 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 1986 | 719 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2009 | 1401 | 0.020 |
Why?
|
| Rabbits | 2 | 2008 | 4894 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 1996 | 3771 | 0.020 |
Why?
|
| Rats | 1 | 2001 | 24252 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 2014 | 2073 | 0.020 |
Why?
|
| Laparoscopy | 1 | 2016 | 2150 | 0.020 |
Why?
|
| Aortic Valve Stenosis | 2 | 1987 | 1965 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 2 | 2004 | 5388 | 0.010 |
Why?
|
| Mitotic Index | 1 | 1984 | 172 | 0.010 |
Why?
|
| Prevalence | 2 | 2008 | 15221 | 0.010 |
Why?
|
| Palpation | 1 | 2004 | 167 | 0.010 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2012 | 941 | 0.010 |
Why?
|
| Genetic Heterogeneity | 1 | 2007 | 733 | 0.010 |
Why?
|
| Equipment Design | 1 | 1992 | 3582 | 0.010 |
Why?
|
| Amino Acid Sequence | 3 | 2002 | 13814 | 0.010 |
Why?
|
| Carcinoma, Medullary | 1 | 2004 | 123 | 0.010 |
Why?
|
| Probability | 1 | 1989 | 2506 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2011 | 2700 | 0.010 |
Why?
|
| Teratoma | 1 | 1986 | 395 | 0.010 |
Why?
|
| Haplotypes | 1 | 2010 | 2779 | 0.010 |
Why?
|
| Massachusetts | 2 | 2010 | 8662 | 0.010 |
Why?
|
| Genital Neoplasms, Female | 1 | 1988 | 523 | 0.010 |
Why?
|
| Models, Biological | 2 | 2011 | 9584 | 0.010 |
Why?
|
| Life Style | 1 | 2014 | 3835 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1999 | 13991 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2013 | 4162 | 0.010 |
Why?
|
| Lysosomes | 1 | 2007 | 893 | 0.010 |
Why?
|
| Signal Transduction | 3 | 2013 | 23404 | 0.010 |
Why?
|
| Ectodysplasins | 1 | 2002 | 11 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1986 | 2646 | 0.010 |
Why?
|
| Chemokine CXCL12 | 1 | 2004 | 465 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2006 | 776 | 0.010 |
Why?
|
| Mucin-1 | 1 | 1986 | 543 | 0.010 |
Why?
|
| Health Surveys | 1 | 2012 | 4036 | 0.010 |
Why?
|
| Kidney | 1 | 2017 | 7184 | 0.010 |
Why?
|
| Clinical Trials as Topic | 3 | 2013 | 7914 | 0.010 |
Why?
|
| Premenopause | 1 | 2005 | 1033 | 0.010 |
Why?
|
| Cross-Sectional Studies | 2 | 2014 | 25039 | 0.010 |
Why?
|
| Hypogonadism | 1 | 1987 | 799 | 0.010 |
Why?
|
| Chi-Square Distribution | 2 | 2002 | 3508 | 0.010 |
Why?
|
| Endocarditis, Bacterial | 1 | 1985 | 455 | 0.010 |
Why?
|
| Vascular Surgical Procedures | 1 | 1990 | 1476 | 0.010 |
Why?
|
| Streptococcal Infections | 1 | 1985 | 638 | 0.010 |
Why?
|
| Metabolic Diseases | 1 | 1987 | 658 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 2002 | 547 | 0.010 |
Why?
|
| Cell Line | 2 | 2011 | 16000 | 0.010 |
Why?
|
| Neurilemmoma | 1 | 1986 | 547 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2009 | 3554 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2011 | 3493 | 0.010 |
Why?
|
| Markov Chains | 1 | 2004 | 969 | 0.010 |
Why?
|
| Stents | 1 | 1992 | 3282 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 2004 | 934 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2009 | 2499 | 0.010 |
Why?
|
| Growth Inhibitors | 1 | 2001 | 385 | 0.010 |
Why?
|
| Diet Surveys | 1 | 2004 | 1173 | 0.010 |
Why?
|
| Radiography | 2 | 1991 | 7023 | 0.010 |
Why?
|
| Coronary Angiography | 4 | 1993 | 4576 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 2007 | 1741 | 0.010 |
Why?
|
| Testicular Neoplasms | 1 | 1986 | 806 | 0.010 |
Why?
|
| Versicans | 1 | 1999 | 33 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2001 | 1581 | 0.010 |
Why?
|
| Decorin | 1 | 1999 | 40 | 0.010 |
Why?
|
| Cricetulus | 1 | 2001 | 818 | 0.010 |
Why?
|
| Genotype | 1 | 2014 | 12952 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2010 | 15520 | 0.010 |
Why?
|
| Pedigree | 1 | 2007 | 4642 | 0.010 |
Why?
|
| COS Cells | 1 | 2001 | 1161 | 0.010 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 1999 | 136 | 0.010 |
Why?
|
| Collagen | 2 | 1999 | 2688 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 2007 | 1376 | 0.010 |
Why?
|
| Collagen Type I | 1 | 2002 | 592 | 0.010 |
Why?
|
| CHO Cells | 1 | 2001 | 1409 | 0.010 |
Why?
|
| Cost Savings | 1 | 2004 | 925 | 0.010 |
Why?
|
| Vegetables | 1 | 2003 | 1182 | 0.010 |
Why?
|
| Stomach Neoplasms | 1 | 2007 | 1332 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2007 | 2251 | 0.010 |
Why?
|
| Bayes Theorem | 1 | 2006 | 2307 | 0.010 |
Why?
|
| Cricetinae | 1 | 2001 | 2475 | 0.010 |
Why?
|
| Child | 3 | 2016 | 77709 | 0.010 |
Why?
|
| Cholesterol | 1 | 1986 | 2919 | 0.010 |
Why?
|
| Homeostasis | 1 | 2008 | 3339 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 2839 | 0.010 |
Why?
|
| Deoxyuracil Nucleotides | 1 | 1996 | 13 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2001 | 2256 | 0.010 |
Why?
|
| Gene Amplification | 1 | 2001 | 1063 | 0.010 |
Why?
|
| Coronary Artery Disease | 2 | 1993 | 6486 | 0.010 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 1996 | 64 | 0.010 |
Why?
|
| Staphylococcal Infections | 1 | 1985 | 1400 | 0.010 |
Why?
|
| Adenofibroma | 1 | 1996 | 25 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2005 | 3505 | 0.010 |
Why?
|
| Histocytological Preparation Techniques | 1 | 1996 | 30 | 0.010 |
Why?
|
| Antioxidants | 1 | 2004 | 1659 | 0.010 |
Why?
|
| Aortic Valve | 1 | 1986 | 1924 | 0.010 |
Why?
|
| Clostridium Infections | 1 | 1983 | 548 | 0.010 |
Why?
|
| Drug Costs | 1 | 2004 | 1105 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 1998 | 625 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 1999 | 552 | 0.010 |
Why?
|
| Proteoglycans | 1 | 1999 | 837 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 1999 | 589 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2004 | 4933 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 12073 | 0.010 |
Why?
|
| Catheterization | 2 | 1991 | 1470 | 0.010 |
Why?
|
| Angiography | 2 | 1991 | 1639 | 0.010 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1999 | 850 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2001 | 1539 | 0.010 |
Why?
|
| GPI-Linked Proteins | 1 | 1996 | 435 | 0.010 |
Why?
|
| Breast Implants | 1 | 1998 | 387 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 1999 | 1730 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 1987 | 20130 | 0.010 |
Why?
|
| Decision Support Techniques | 1 | 2004 | 1956 | 0.010 |
Why?
|
| Psoriasis | 1 | 2002 | 902 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2003 | 4222 | 0.010 |
Why?
|
| von Willebrand Factor | 1 | 1997 | 669 | 0.010 |
Why?
|
| Safety | 1 | 1998 | 1186 | 0.010 |
Why?
|
| Transfection | 1 | 2001 | 5895 | 0.010 |
Why?
|
| Skin Transplantation | 1 | 1998 | 1074 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 1997 | 578 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2001 | 3773 | 0.010 |
Why?
|
| Contrast Media | 1 | 2006 | 5300 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2006 | 4042 | 0.010 |
Why?
|
| Cell Movement | 1 | 2004 | 5218 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 1983 | 3037 | 0.010 |
Why?
|
| RNA | 1 | 2002 | 2749 | 0.010 |
Why?
|
| Family | 1 | 2002 | 3147 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 1997 | 2971 | 0.010 |
Why?
|
| Spinal Neoplasms | 1 | 1998 | 760 | 0.010 |
Why?
|
| Esophageal Diseases | 1 | 1992 | 167 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2004 | 3444 | 0.010 |
Why?
|
| Cell Death | 1 | 1996 | 1707 | 0.010 |
Why?
|
| Radioisotope Teletherapy | 1 | 1989 | 18 | 0.010 |
Why?
|
| Coronary Thrombosis | 1 | 1993 | 495 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1997 | 3873 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 18034 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2001 | 5867 | 0.010 |
Why?
|
| Surgical Flaps | 1 | 1998 | 1640 | 0.010 |
Why?
|
| Mucous Membrane | 1 | 1992 | 673 | 0.000 |
Why?
|
| Constriction, Pathologic | 1 | 1991 | 1107 | 0.000 |
Why?
|
| Genitalia, Female | 1 | 1988 | 146 | 0.000 |
Why?
|
| Perineum | 1 | 1988 | 211 | 0.000 |
Why?
|
| Hematoporphyrin Derivative | 1 | 1985 | 10 | 0.000 |
Why?
|
| Urethra | 1 | 1988 | 408 | 0.000 |
Why?
|
| Comorbidity | 1 | 2001 | 10388 | 0.000 |
Why?
|
| DNA Damage | 1 | 1996 | 2432 | 0.000 |
Why?
|
| Methods | 1 | 1986 | 1129 | 0.000 |
Why?
|
| Intraoperative Period | 1 | 1987 | 520 | 0.000 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1997 | 4424 | 0.000 |
Why?
|
| Smoking | 1 | 2002 | 8987 | 0.000 |
Why?
|
| Emergencies | 1 | 1991 | 1170 | 0.000 |
Why?
|
| Postoperative Period | 1 | 1990 | 1842 | 0.000 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1985 | 228 | 0.000 |
Why?
|
| Cervix Uteri | 1 | 1987 | 590 | 0.000 |
Why?
|
| Deafness | 1 | 1987 | 458 | 0.000 |
Why?
|
| Blindness | 1 | 1987 | 615 | 0.000 |
Why?
|
| Feasibility Studies | 1 | 1993 | 5077 | 0.000 |
Why?
|
| Uterus | 1 | 1987 | 711 | 0.000 |
Why?
|
| Europe | 1 | 1989 | 3338 | 0.000 |
Why?
|
| Muscle, Skeletal | 1 | 1998 | 4925 | 0.000 |
Why?
|
| Intraoperative Care | 1 | 1986 | 767 | 0.000 |
Why?
|
| Endoscopy | 1 | 1992 | 1787 | 0.000 |
Why?
|
| Esophageal Neoplasms | 1 | 1992 | 1585 | 0.000 |
Why?
|
| Syndrome | 1 | 1987 | 3252 | 0.000 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1983 | 876 | 0.000 |
Why?
|
| Brachytherapy | 1 | 1988 | 1248 | 0.000 |
Why?
|
| Boston | 1 | 1992 | 9312 | 0.000 |
Why?
|
| Colon | 1 | 1987 | 1772 | 0.000 |
Why?
|
| Postoperative Complications | 2 | 1992 | 15297 | 0.000 |
Why?
|
| Physical Examination | 1 | 1985 | 1237 | 0.000 |
Why?
|
| Electrocardiography | 1 | 1990 | 6442 | 0.000 |
Why?
|
| Patient Care Team | 1 | 1987 | 2531 | 0.000 |
Why?
|
| Palliative Care | 1 | 1986 | 3493 | 0.000 |
Why?
|
| Myocardial Infarction | 1 | 1990 | 11718 | 0.000 |
Why?
|